Cytosorbents (NASDAQ:CTSO) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO) in a report released on Thursday. The firm set a “hold” rating on the medical research company’s stock.

Separately, D. Boral Capital restated a “buy” rating and set a $10.00 price target on shares of Cytosorbents in a report on Tuesday. Two investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.67.

Cytosorbents Trading Down 2.0 %

NASDAQ CTSO opened at $0.97 on Thursday. The firm’s 50 day moving average price is $1.07 and its two-hundred day moving average price is $1.04. The stock has a market cap of $53.04 million, a price-to-earnings ratio of -2.69 and a beta of 0.78. Cytosorbents has a twelve month low of $0.70 and a twelve month high of $1.61. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97.

Cytosorbents (NASDAQ:CTSO) last announced its quarterly earnings data on Monday, March 31st. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.04. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The firm had revenue of $9.20 million during the quarter, compared to the consensus estimate of $10.09 million. Equities analysts anticipate that Cytosorbents will post -0.3 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Geode Capital Management LLC raised its stake in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock worth $701,000 after purchasing an additional 32,415 shares in the last quarter. Skylands Capital LLC increased its holdings in Cytosorbents by 1.0% in the fourth quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock worth $2,531,000 after buying an additional 26,195 shares during the last quarter. Millennium Management LLC bought a new position in Cytosorbents during the fourth quarter valued at approximately $30,000. Northern Trust Corp lifted its stake in Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company’s stock valued at $83,000 after acquiring an additional 16,701 shares during the last quarter. Finally, Raymond James Financial Inc. bought a new stake in Cytosorbents in the fourth quarter worth approximately $99,000. Hedge funds and other institutional investors own 32.87% of the company’s stock.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.